A comparative,prospective, nationwide study of Inflectra (biosimilar monoclonal antibody) and Remicade for inducing and maintaining remission in inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) in Hungarian patients.

Trial Profile

A comparative,prospective, nationwide study of Inflectra (biosimilar monoclonal antibody) and Remicade for inducing and maintaining remission in inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) in Hungarian patients.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Hospira
  • Most Recent Events

    • 19 Oct 2016 Results (n= 291) presented at the 24th United European Gastroenterology Week
    • 20 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top